share_log

bluebird bio | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

bluebird bio | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

bluebird bio | S-8：员工福利计划证券登记
美股SEC公告 ·  11/14 16:37

Moomoo AI 已提取核心信息

On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.
On November 14, 2024, bluebird bio, Inc., a biotechnology company incorporated in Delaware, filed a Registration Statement on Form S-8 with the Securities and Exchange Commission. This filing was made to register an additional 15 million shares of common stock under the company's 2023 Incentive Award Plan, following the approval by stockholders on November 6, 2024, to increase the aggregate number of shares authorized for issuance from 5.2 million to 20.2 million shares. The Form S-8 filing incorporates by reference the information contained in the company's previous registration statement relating to the 2023 Plan. The company's President and Chief Executive Officer, Andrew Obenshain, along with other officers and directors, signed the registration statement, indicating compliance with the requirements of the Securities Act of 1933.
2024年11月14日，bluebird bio, Inc.是一家注册于特拉华州的生物技术公司，向证券交易委员会提交了S-8表格的注册申报。这份申请旨在根据公司2023年激励奖励计划注册额外的1500万股普通股，此前在2024年11月6日股东获批将授权发行的股份总数从520万增加至2020万股。S-8表格注册申报通过引用方式整合了公司之前与2023年计划相关的注册申报中的信息。公司的总裁兼首席执行官Andrew Obenshain与其他高管和董事签署了注册申报，表示遵守1933年证券法的要求。
2024年11月14日，bluebird bio, Inc.是一家注册于特拉华州的生物技术公司，向证券交易委员会提交了S-8表格的注册申报。这份申请旨在根据公司2023年激励奖励计划注册额外的1500万股普通股，此前在2024年11月6日股东获批将授权发行的股份总数从520万增加至2020万股。S-8表格注册申报通过引用方式整合了公司之前与2023年计划相关的注册申报中的信息。公司的总裁兼首席执行官Andrew Obenshain与其他高管和董事签署了注册申报，表示遵守1933年证券法的要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间